Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > BUSINESS
BUSINESS
- Japanese Drug Majors Ratcheting Up Moves in CAR-T Space
September 6, 2017
- Spera Pharma Begins Business Capitalizing on “Takeda’s” Track Record, Aims to Become Japan’s No. 1 CDMO
September 6, 2017
- Takeda in CAR-T Therapy Pact with NCC/Yamaguchi Univ. Spin-Out
September 5, 2017
- Mitsubishi Tanabe to Beef Up Marketing System in Field of Autoimmune Diseases, Plans to Expand Expert Sales Force
September 5, 2017
- Aspen Completes Takeover of 4 Kyowa Kirin Brands
September 4, 2017
- BIKEN-Mitsubishi Tanabe Vaccine JV Now Up and Running
September 4, 2017
- Seikagaku, Ono Ink Definitive Deal on Osteoarthritis Treatment
September 4, 2017
- Yamaha Enters Medical Field with Cell Handler, a Device to Support Drug Discovery
September 4, 2017
- Mirogabalin Delivers Positive Data for Diabetic Peripheral Neuropathic Pain: Daiichi Sankyo
September 1, 2017
- Daiichi Sankyo Ditches CL-108 Deal, Takes 27.8 Billion Yen Impaired Loss
September 1, 2017
- Daiichi Sankyo Denies Report on AZ’s Acquisition Offer
September 1, 2017
- Opdivo Clinches Batch of New Indications in South Korea
August 31, 2017
- Praluent Self-Injection Possible from Sept. 1; Repatha Auto Mini Doser Approved
August 31, 2017
- Daiichi Sankyo Share Trade Halted after Report on AZ’s Acquisition Offer
August 31, 2017
- Trerief Filed for Parkinsonism in DLB: Sumitomo Dainippon
August 31, 2017
- MSD to Cut 250 Jobs as It Foresees Portfolio Changes
August 31, 2017
- Daiichi Sankyo’s DS-8201 Gets Breakthrough Therapy Designation
August 31, 2017
- Fujifilm Holdings Aims to Achieve 500 Billion Yen in Healthcare Sales in FY2019
August 31, 2017
- Mitsubishi Tanabe Chief Looks to Tap Canaglu’s CV Outcome Data to Boost Sales
August 30, 2017
- Boston Pharma Gets Rights to Daiichi Sankyo’s Preclinical RET Inhibitor
August 30, 2017
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…